Linrodostat mesylate is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase III program in Muscle Invasive Bladder Cancer (MIBC). According to Globaldata, it is involved in 24 clinical trials, of which 16 were completed, 7 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Linrodostat mesylate’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Linrodostat mesylate is expected to reach an annual total of $20 mn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Linrodostat mesylate Overview
Linrodostat mesylate is under development for the treatment of endometrial carcinosarcoma, cutaneous melanoma, non-muscle invasive bladder cancer (NMIBC), advanced malignancy, muscle-invasive bladder cancer, non-small cell lung cancer, advanced solid tumors such as Esophageal cancer, Adenocarcinoma Of The Gastroesophageal Junction, metastatic hepatocellular carcinoma, advanced gastric cancer, advanced renal cell carcinoma and hematological tumor. It is administered orally as a capsule or a film-coated tablet. The drug candidate acts by targeting IDO1. It was also under development for the treatment of previously untreated metastatic melanoma, recurrent/metastatic head and neck squamous cell carcinoma and squamous or non-squamous non-small cell lung cancer, bladder cancer and cervical cancer.
Bristol-Myers Squibb Overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
The company reported revenues of (US Dollars) US$46,159 million for the fiscal year ended December 2022 (FY2022), a decrease of 0.5% over FY2021. The operating profit of the company was US$9,665 million in FY2022, compared to an operating profit of US$8,615 million in FY2021. The net profit of the company was US$6,327 million in FY2022, compared to a net profit of US$6,994 million in FY2021.
For a complete picture of Linrodostat mesylate’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.